 Unum Therapeutics Inc. UMRX, a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced it has completed Cohort 1 enrollment with no dose-limiting toxiticies DLT observed in the ATTCK-34-01 Phase 1 trial evaluating Unums novel Antibody-Coupled T cell Receptor investigational therapy, ACTR707, together with trastuzumab for the treatment of patients with HER2 advanced cancers. Patient enrollmentdefined as patients who have signed informed consent forms and met all eligibility criteriais complete with five patients in this first cohort in the ATTCK-34-01 Phase 1 trial, a multicenter, open-label, single-arm, dose-escalation trial. 